FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3106350466> ?p ?o ?g. }

• W3106350466 endingPage "472" @default.
• W3106350466 startingPage "464" @default.
• W3106350466 abstract "Mineralocorticoid receptor (MR) blockers are very beneficial for patients with hypertension and primary aldosteronism (PA). We investigated the efficacy and safety of a newly available nonsteroidal MR blocker, esaxerenone, in Japanese patients with hypertension and PA. A multicenter, open-label study was conducted in Japan between October 2016 and July 2017. Patients with hypertension and PA received 12 weeks of treatment with esaxerenone, initiated at 2.5 mg/day and escalated to 5 mg/day during week 2 or 4 of treatment, based on individual response. The only other permitted antihypertensive therapies were stable dosages of a Ca2+ channel blocker or α-blocker. The primary efficacy outcome was a change in sitting systolic and diastolic blood pressure (SBP/DBP) from baseline to the end of treatment. Forty-four patients were included; dose escalation to 5 mg/day was implemented for 41 of these patients. Significant decreases in SBP and DBP were observed (point estimates [95% confidence interval] -17.7 [-20.6, -14.7] and -9.5 [-11.7, -7.3] mmHg, respectively; both p < 0.0001 at the end of treatment). Significant BP reductions were evident from week 2 and continued through to week 8; BP remained stable until week 12. The antihypertensive effect of esaxerenone on SBP was significantly greater in females and in patients receiving monotherapy. The major drug-related adverse events were serum K+ increase and estimated glomerular filtration rate decrease (both 4.5%, n = 2); no gynecomastia or breast pain was observed. We conclude that esaxerenone is a potent MR blocker with favorable efficacy and safety profiles in patients with hypertension and PA." @default.
• W3106350466 created "2020-11-23" @default.
• W3106350466 creator A5003990451 @default.
• W3106350466 creator A5008916675 @default.
• W3106350466 creator A5017829907 @default.
• W3106350466 creator A5021267745 @default.
• W3106350466 creator A5021311208 @default.
• W3106350466 creator A5025921038 @default.
• W3106350466 creator A5046934750 @default.
• W3106350466 creator A5066495888 @default.
• W3106350466 creator A5077665206 @default.
• W3106350466 creator A5084913194 @default.
• W3106350466 date "2020-11-16" @default.
• W3106350466 modified "2023-10-18" @default.
• W3106350466 title "Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism" @default.
• W3106350466 cites W1797367453 @default.
• W3106350466 cites W1817639972 @default.
• W3106350466 cites W1975885226 @default.
• W3106350466 cites W1976246655 @default.
• W3106350466 cites W1977186839 @default.
• W3106350466 cites W1984938230 @default.
• W3106350466 cites W2001374641 @default.
• W3106350466 cites W2018109782 @default.
• W3106350466 cites W2019439141 @default.
• W3106350466 cites W2037296473 @default.
• W3106350466 cites W2059489179 @default.
• W3106350466 cites W2064532153 @default.
• W3106350466 cites W2076825380 @default.
• W3106350466 cites W2099583783 @default.
• W3106350466 cites W2107999636 @default.
• W3106350466 cites W2129950671 @default.
• W3106350466 cites W2136936562 @default.
• W3106350466 cites W2147713192 @default.
• W3106350466 cites W2150734413 @default.
• W3106350466 cites W2152094259 @default.
• W3106350466 cites W2168924012 @default.
• W3106350466 cites W2172086404 @default.
• W3106350466 cites W2173089390 @default.
• W3106350466 cites W2174401463 @default.
• W3106350466 cites W2273248750 @default.
• W3106350466 cites W2290633895 @default.
• W3106350466 cites W2325273457 @default.
• W3106350466 cites W2600438012 @default.
• W3106350466 cites W2617388174 @default.
• W3106350466 cites W2766470307 @default.
• W3106350466 cites W2785058944 @default.
• W3106350466 cites W2800509413 @default.
• W3106350466 cites W2802617131 @default.
• W3106350466 cites W2926482915 @default.
• W3106350466 cites W2945989863 @default.
• W3106350466 cites W2954234894 @default.
• W3106350466 cites W2955032344 @default.
• W3106350466 cites W2963283134 @default.
• W3106350466 cites W2991065707 @default.
• W3106350466 doi "https://doi.org/10.1038/s41440-020-00570-5" @default.
• W3106350466 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8019657" @default.
• W3106350466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33199881" @default.
• W3106350466 hasPublicationYear "2020" @default.
• W3106350466 type Work @default.
• W3106350466 sameAs 3106350466 @default.
• W3106350466 citedByCount "24" @default.
• W3106350466 countsByYear W31063504662021 @default.
• W3106350466 countsByYear W31063504662022 @default.
• W3106350466 countsByYear W31063504662023 @default.
• W3106350466 crossrefType "journal-article" @default.
• W3106350466 hasAuthorship W3106350466A5003990451 @default.
• W3106350466 hasAuthorship W3106350466A5008916675 @default.
• W3106350466 hasAuthorship W3106350466A5017829907 @default.
• W3106350466 hasAuthorship W3106350466A5021267745 @default.
• W3106350466 hasAuthorship W3106350466A5021311208 @default.
• W3106350466 hasAuthorship W3106350466A5025921038 @default.
• W3106350466 hasAuthorship W3106350466A5046934750 @default.
• W3106350466 hasAuthorship W3106350466A5066495888 @default.
• W3106350466 hasAuthorship W3106350466A5077665206 @default.
• W3106350466 hasAuthorship W3106350466A5084913194 @default.
• W3106350466 hasBestOaLocation W31063504661 @default.
• W3106350466 hasConcept C126322002 @default.
• W3106350466 hasConcept C126894567 @default.
• W3106350466 hasConcept C134018914 @default.
• W3106350466 hasConcept C189135053 @default.
• W3106350466 hasConcept C197934379 @default.
• W3106350466 hasConcept C2778525890 @default.
• W3106350466 hasConcept C2780233176 @default.
• W3106350466 hasConcept C2780356492 @default.
• W3106350466 hasConcept C71924100 @default.
• W3106350466 hasConcept C84393581 @default.
• W3106350466 hasConceptScore W3106350466C126322002 @default.
• W3106350466 hasConceptScore W3106350466C126894567 @default.
• W3106350466 hasConceptScore W3106350466C134018914 @default.
• W3106350466 hasConceptScore W3106350466C189135053 @default.
• W3106350466 hasConceptScore W3106350466C197934379 @default.
• W3106350466 hasConceptScore W3106350466C2778525890 @default.
• W3106350466 hasConceptScore W3106350466C2780233176 @default.
• W3106350466 hasConceptScore W3106350466C2780356492 @default.
• W3106350466 hasConceptScore W3106350466C71924100 @default.
• W3106350466 hasConceptScore W3106350466C84393581 @default.
• W3106350466 hasIssue "4" @default.
• W3106350466 hasLocation W31063504661 @default.

• next